Charles River Laboratories International, Inc. (CRL) News
Filter CRL News Items
CRL News Results
|Loading, please wait...|
CRL News Highlights
- CRL's 30 day story count now stands at 40.
- Over the past 21 days, the trend for CRL's stories per day has been choppy and unclear. It has oscillated between 1 and 23.
- The most mentioned tickers in articles about CRL are BEAT, BIO and TNDM.
Latest CRL News From Around the Web
Below are the latest news stories about Charles River Laboratories International Inc that investors may wish to consider to help them evaluate CRL as an investment opportunity.
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares.
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysts Offer Insights on Services Companies: Charles River Labs (CRL), Cheesecake Factory (CAKE) and Trade Desk (TTD)
There's a lot to be optimistic about in the Services sector as 3 analysts just weighed in on Charles River Labs (CRL – Research Report), Cheesecake Factory (CAKE – Research Report) and Trade Desk (TTD – Research Report) with bullish sentiments. Charles River Labs (CRL) In a report released today, Donald Hooker from KeyBanc maintained a Buy rating on Charles River Labs, with a price target of $390.00. The company's shares closed last Wednesday at $305.28. Hooker has an average return of 13.7% and a 52.6% success rate. Patterson covers the Technology sector, focusing on stocks such as NerdWallet, Inc. Class A, Spotify Technology SA, and Alphabet Class A.
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.
Charles River Laboratories International Inc''s (NYSE: CRL ) Q4 sales increased 14.4% Y/Y to $905.1 million , beating the consensus of $888.27 million. Acquisitions contributed 5.9% to consolidated fourth-quarter revenue growth. Organic revenue growth was 10.5%, driven by contributions from all three business segments. Adjusted EPS reached $2.49 higher than $2.39 posted a year ago and … Full story available on Benzinga.com
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q4 2021 Results - Earnings Call Transcript
No summary available.
Charles River Laboratories International <
No summary available.